课题基金 / 基金详情

Wider application of small-for-size partial liver grafting by gene transfer using teromerase reverse transcriptase (TERT).

Wider application of small-for-size partial liver grafting by gene transfer using teromerase reverse transcriptase (TERT).
使用端粒酶逆转录酶(TERT)进行基因转移的小型部分肝移植的更广泛应用。
批准号:
13671243
负责人:
SOEJIMA Yuji
金额:
$2.3万
依托单位国家:
日本
项目类别:
Grant-in-Aid for Scientific Research (C)
财政年份:
2001
资助国家:
日本
项目状态:
已结题
起止时间:
2001 至 2002

项目摘要

项目成果

SOEJIMA Yuji的其他基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
1. Development of rat liver transplantation model using small-for-size graft:Rat liver transplantation model using small-for-size graft (30% of whole liver volume) was established, in which 100% 3-day mortality was assured.2. Development of gene-transfer technique:(1) Gene transfer using electroporation (EP) technique:An EP-mediated teromerase reverse transcriptase (TERT) gene transfer into human hepatocyte primary cultrure was carried out. A 10% of transfection effectivcess was achieved. However, gene transfer of TERT did not extend the survival of the cells. A direct damege to hepatocytes by EP technique was suggested.(2) Gene transfer into cold-preserved rat liver:Ex vivo EP-mediated or hydrodynamic gene transfer into a cold-preserved (UW solution, 4℃) rat liver graft was evaluated using rat liver transplantation model. The luciferase gene expression in the graft after liver transplantation was found to be increased. However, significant graft damage due to a gene transfer was observed.Therefore, development of an alternative strategy using nano-carrier was indicated.(3) In vivo IL-12 gene transfer using EP technique under immunosuppression:Using mice model carrying hepatoma cells (MH134), in vivo IL-12 gene transfer using EP technique was carried out under immunosuppression by FK506. Intratumoral administration of mIL-12 vector elevated intratumoral IL-12 and IFN-γ on the days 7 and 14 of transfer and significantly inhibited not only the growth of HCC, but also the angiogenesis in the tumor through expression of antiangiogenetic chemokaine IP-10.(4) Gene transfer using hydrodynamic method:As an alternative to EP technique, gene transfer using hydrodynamic method was established. Expression of inciferase gene peaked at 4 hour after injection. The mechanism of the method has not been elucidated so far, thus further investigation was indicated.
期刊论文(19)
专著(0)
科研奖励(0)
会议论文
Tanaka S. et al.: "Oncogenic signal transduction and therapeutic strategy for hepatocellular carcinama."Surgery. 131. 142-147 (2002)
Tanaka S. 等人:“肝细胞癌的致癌信号转导和治疗策略。”外科。
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
Shinji Tanaka et al.: "Clinicopathologic risk factors for recurrence after a curative hepatic resectionfor henatocellular carcinoma"Surgery. 131. 148-152 (2002)
Shinji Tanaka 等人:“肝细胞癌治愈性肝切除术后复发的临床病理学危险因素”手术。
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
Soejima Y. et al.: "Feasibility of duct-to-duct biliary reconstruction in left-lobe adult-living-donor liver transplantation."Transplantation. 785. 557-559 (2003)
Soejima Y. 等人:“左叶成人活体供体肝移植中管对管胆道重建的可行性。”移植。
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
Yuji Soejima et al.: "Safety and Risk of Using Pediatric Donor Livers in Adult Liver Transplantation"Liver Transplantation. 7. 41-47 (2001)
Yuji Soejima 等人:“成人肝脏移植中使用儿童供体肝脏的安全性和风险”肝脏移植。
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
15
    The amount and quality of sleep in physical education college students: relationships with depression and health-related QOL
    Development of novel gene-therapy using IL-12 and DNA nanoassociate bearing hyaluronan-glycocalyx for recurrent hepatocellular carcinoma after liver transplantation
    • 批准号:
      20591528
    • 项目类别:
      Grant-in-Aid for Scientific Research (C)
    • 资助金额:
      $3.08万
    • 财政年份:
      2008
    • 负责人:
      SOEJIMA Yuji
    • 依托单位:
    Development of the new immunological tolerance induction which uses Notch ligands in islet transplantation
    • 批准号:
      18591414
    • 项目类别:
      Grant-in-Aid for Scientific Research (C)
    • 资助金额:
      $2.43万
    • 财政年份:
      2006
    • 负责人:
      SOEJIMA Yuji
    • 依托单位: